Merck Gets Priority Review for Keytruda in Third-Line SCLC

Merck & Co., Inc. MRK announced that the FDA has granted priority review to yet another supplemental biologics license application (sBLA) for its PD-L1 inhibitor, Keytruda. In the latest sBLA, Merck is looking for FDA’s approval of Keytruda as monotherapy for advanced small cell lung cancer ("SCLC") in third or later-line setting. With the FDA granting priority review, a decision is expected on Jun 17, 2019.